Acitretin
Orphan DrugFDA Approved
Description
Acitretin is a second-generation retinoid used in the treatment of severe disorders of keratinization including ichthyosis. It regulates cell differentiation, proliferation, and keratinization processes in the skin. The drug has demonstrated efficacy in various forms of congenital ichthyosis and other severe dermatological conditions.
Indications & Therapeutic Use
Severe psoriasis, congenital ichthyosis, Darier disease, palmoplantar keratoderma
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Acitretin
| Generic Name | Acitretin |
| Brands | 1 brand available |
| Active Ingredient | Acitretin |
| Drug Class | Severe psoriasis |
| Manufacturer | Stiefel Laboratories |
| Dosage Forms | Oral capsule, 10mg, 25mg |
| Medical Code | D05BB02 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes